← Eichor
Condition: High Risk Localised Prostate Carcinoma Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: High Risk Localised Prostate Carcinoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Randomised Trial of Cabazitaxel, Docetaxel, Mitoxantrone or Satraplatin (CDMS) Plus Surgery for Prostate Cancer Patien
Phase 2/Phase 3 · 2 location(s) · Shanghai Jiao Tong University School of Medicine · NCT03258320High Intensity Focused Ultrasound in Prostate Cancer
Phase 2 · 1 location(s) · University of Florida · NCT06402357Neoadjuvant High Dose Rate Brachytherapy Prior to Radical Prostatectomy in Patients With Prostate Cancer
Phase 1/Phase 2 · 1 location(s) · The Methodist Hospital Research Institute · NCT07182279Safety of Dose Escalation in Definitive Hypofractionated Radiation Therapy and Hormone Therapy With SpaceOAR TM for Pati
Phase 2 · 1 location(s) · Samsung Medical Center · NCT06461793Efficacy and Safety of Radical Prostatectomy (RP) With or Without Salvage Radiotherapy Versus RP With Extended Pelvic Ly
NA · 1 location(s) · Ruijin Hospital · NCT0711599224 Gy in One Fraction Urethral-sparing "HDR Like" SBRT for Prostate Cancer
NA · 1 location(s) · IRCCS San Raffaele · NCT05936736Clinical Study of HIFU for Localized Prostate Cancer
Phase N/A · 1 location(s) · RenJi Hospital · NCT06362577Multi-omic Approach to Study HDR Brachytherapy for Favorable Risk and Low Tier Intermediate Risk Prostate Cancer
Phase N/A · 1 location(s) · British Columbia Cancer Agency · NCT06200974High Dose-Rate Brachytherapy and Stereotactic Body Radiotherapy for the Treatment of Prostate Adenocarcinoma
NA · 1 location(s) · Jonsson Comprehensive Cancer Center · NCT04945642Neoadjuvant Pembrolizumab Plus Androgen Axis Blockade Prior to Prostatectomy for High Risk Localized Prostate Cancer
Phase 2 · 1 location(s) · Mark Garzotto, MD · NCT03753243Artificial Intelligence to Personalize Prostate Cancer Treatment (the HypoElect Trial)
Phase 2 · 1 location(s) · German Oncology Center, Cyprus · NCT06582446A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-r
Phase 2 · 2 location(s) · University of Chicago · NCT05726292Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer
Phase 2 · 9 location(s) · University of British Columbia · NCT04812366Focal Ablation With Focal Cryotherapy or HIFU for the Treatment of Men With Localized Prostate Cancer
NA · 1 location(s) · University of California, Davis · NCT06178354Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA P
Phase 2 · 1 location(s) · Baptist Health South Florida · NCT07455903Focal Therapy for Localized Prostate Cancer
Phase N/A · 1 location(s) · University of California, San Diego · NCT06270043Study Evaluating the Efficacy and Safety of Darolutamide and Stereotactic Dose Escalated Radiotherapy in Patients With L
Phase 3 · 6 location(s) · UNICANCER · NCT06625970Two-fraction HDR Monotherapy for Localized Prostate Cancer
NA · 1 location(s) · University of California, San Francisco · NCT05665738A Study to Learn How Well a Combination of Darolutamide and Androgen Deprivation Therapy (ADT) Works as a Treatment Befo
Phase 2 · 23 location(s) · Bayer · NCT07450599Neoadjuvant Lu-177-PSMA-617 in Patients With High Risk Localized Prostate Cancer Undergoing Radical Prostatectomy
Phase 2 · 3 location(s) · Hackensack Meridian Health · NCT06798558Artificial Intelligence Driven Personalisation of Radiotherapy and Concomitant Androgen Deprivation Therapy for Prostate
Phase 2 · 1 location(s) · German Oncology Center, Cyprus · NCT06772441Evaluation of Neoadjuvant Xaluritamig in Localized Prostate Cancer
Phase 1 · 9 location(s) · Amgen · NCT06613100Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT04947254A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate
Phase 3 · 342 location(s) · AstraZeneca · NCT06952803Focal Therapy for Prostate Cancer Using HIFU
NA · 1 location(s) · University College, London · NCT01194648Addition of Focal Boost to Primary Radiotherapy for Prostate Cancer in 12 or 20 Fractions
NA · 3 location(s) · Rigshospitalet, Denmark · NCT07343349A Study of 2141-V11 in Combination With Standard Treatments in People With Prostate Cancer
Phase 2 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT06347705Pilot Study of (MR) Imaging With Pyruvate (13C) to Detect High Grade Prostate Cancer
EARLY_Phase 1 · 1 location(s) · Ivan de Kouchkovsky, MD · NCT02526368Accuracy of 18F-rhPSMA-7.3 PET/ MRI for Prediction of Lymph Node Metastasis in Localized High-Risk Prostate Cancer
NA · 1 location(s) · Mayo Clinic · NCT06389786Dose Escalation For INtraprostatic LEsions
Phase 2 · 1 location(s) · Ottawa Hospital Research Institute · NCT05851547
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.